107285-30-3

Basic information

• Product Name: 3-[2-(3-CHLORO-PHENYL)-ETHYL]-PYRIDINE-2-CARBOXYLIC ACID TERT-BUTYLAMIDE
• Synonyms: 3-[2-(3-CHLORO-PHENYL)-ETHYL]-PYRIDINE-2-CARBOXYLIC ACID TERT-BUTYLAMIDE;2-Pyridinecarboxamide, 3-[2-(3-chlorophenyl)ethyl]-N-(1,1-dimethylethyl)-;N-(tert-Butyl)-3-(3-chlorophenethyl)picolinaMide
• CAS NO: 107285-30-3
• Molecular Formula: C₁₈H₂₁ClN₂O
• Molecular Weight: 316.82514
• Mol File: 107285-30-3.mol

Chemical Properties

• Melting Point: 45-46 °C(Solv: hexane (110-54-3))
• Boiling Point: 461.3±40.0 °C(Predicted)
• Appearance: /
• Density: 1.139±0.06 g/cm3(Predicted)
• PKA: 13.85±0.46(Predicted)
• CAS DataBase Reference: 3-[2-(3-CHLORO-PHENYL)-ETHYL]-PYRIDINE-2-CARBOXYLIC ACID TERT-BUTYLAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-[2-(3-CHLORO-PHENYL)-ETHYL]-PYRIDINE-2-CARBOXYLIC ACID TERT-BUTYLAMIDE(107285-30-3)
• EPA Substance Registry System: 3-[2-(3-CHLORO-PHENYL)-ETHYL]-PYRIDINE-2-CARBOXYLIC ACID TERT-BUTYLAMIDE(107285-30-3)

Safety Data

• Hazardous Substances Data: 107285-30-3(Hazardous Substances Data)

Upstream product

• 32998-95-1 N-tert-butyl-3-methylpyridine-2-carboxamide 
• 620-20-2 1-Chloro-3-chloromethyl-benzene 
• 20970-75-6 2-cyano-3-methylpyridine 

Downstream Products

• 31255-57-9 3-[2-(3-chlorophenyl)ethyl]-2-pyridine-carbonitrile 
• 117810-92-1 (4-(8-chloro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(6H)-ylidene)piperidin-1-yl)(phenyl)methanone 
• 130642-50-1 {3-[2-(3-Chloro-phenyl)-ethyl]-pyridin-2-yl}-(1-methyl-piperidin-4-yl)-methanone 
• 117796-52-8 N-acetyl desloratadine 
• 130642-45-4 1-[4-(8-Chloro-5,6-dihydro-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-cyclohexyl]-ethanone 
• 130642-69-2 8-Chloro-11-(4-methoxymethylene-cyclohexylidene)-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine 
• 117810-61-4 N-formyldesloratadine 
• 130642-70-5 4-(8-Chloro-5,6-dihydro-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-cyclohexanecarbaldehyde 
• 130642-68-1 4-(8-Chloro-5,6-dihydro-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-cyclohexanone 
• 100643-71-8 descarboethoxyloratadine 
• 31251-41-9 8-chloro-5,6-dihydro-11H-Benzo[5,6]cyclohepta[1,2-b]pyridin-11-one 
• 38092-89-6 N-methyldesloratadine 
• 119770-60-4 1-(METHYL-4-PIPERIDINYL)[3-(2-(3-CHLORO-PHENYL)ETHYL)-2-PYRIDINYL]METHANONE HYDROCHLORIDE 
• 79794-75-5 loratadine 

Relevant articles and documents

Preparation method of loratadine intermediate 3-[2-(3-chlorphenyl) ethyl]-2-pyridinecarbonitrile

The invention provides a preparation method as shown in a formula I and a preparation method of 3-[2-(3-chlorphenyl) ethyl]-2-pyridinecarbonitrile. The invention provides a novel method for preparing a loratadine intermediate.

Preparation method of loratadine

The invention provides a preparation method of loratadine. The method comprises the following steps: taking 2-cyano-3-methylpyridine as a raw material, and carrying out Ritter reaction, m-chlorobenzylchloride condensation, POCl3 deprotection group, Grignard reaction, cyclization and ethyl chloroformate substitution to obtain 4(8-chlorine-5, 6-dihydro-11H-benzo-[5, 6]cycloheptano[1, 2-b]pyridine-11-subunit)-1-piperidine carboxylic acid ethyl ester. According to the invention, a post-treatment process is innovated, and a new cyclization system is adopted to catalyze the reaction, so that the use of high-cost and high-toxicity strong acid is avoided, and a milder and more economical synthesis method is provided for industrial production.

Preparation method of loratadine intermediate

The invention provides a preparation method of a loratadine intermediate, and belongs to the technical field of chemical medicine preparation. The preparation method comprises the following steps: by taking trimethyl-2-cyanopyridine as an initial synthesis raw material, protecting cyano by tert-butyl alcohol to obtain an intermediate 2, performing nucleophilic substitution on the intermediate 2 and benzyl chloride to obtain an intermediate 3, performing deprotection by using phosphorus oxychloride to obtain an intermediate 4, and finally performing addition with a Grignard reagent and obtaining a key intermediate 1 of loratadine under an acidic condition.

Preparation process of 3-[2-(3-chlorphenyl)ethyl]-2-pyridinecarboxylic acid

The invention provides a preparation process of 3-[2-(3-chlorphenyl)ethyl]-2-pyridinecarboxylic acid (as shown in formula II). The reaction equation is as shown in the description, wherein substituent R is hydrogen, tertiary butyl, phenyl or substituted p

Aza-analogue dibenzepinone scaffolds as p38 mitogen-activated protein kinase inhibitors:Design, synthesis, and biological data of inhibitors with improved physicochemical properties

We recently described a promising novel class of p38 mitogen activated protein (MAP) kinase inhibitors with dibenzepinone-scaffolds. To optimize their physicochemical properties, characterized by calculated log P values and measured lipophilicity (chromatographic hydrophobicity index=CHI), we synthesized aza-analogue dibenzepinones. Here, we present the synthesis and biological data of compounds with the novel aza-dibenzepinone scaffolds. Although these aza-analogues revealed an improved aqueous solubility, introduction of nitrogen was not effective in the p38 MAPK enzyme assay.

DIPEPTIDYL PEPTIDASE-IV INHIBITORS

The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes.

Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases

A method of inhibiting Ras function and therefore inhibiting cellular growth is disclosed. The method comprises the administration of a compound of Formula 1.0 Also disclosed are novel compounds of the formulas: Also disclosed are processes for making 3-substituted compounds of the Formulas 1.1, 1.2 and 1.3. Further disclosed are novel compounds which are intermediates in the processes for making the 3-substituted compounds of Formulas 1.1, 1.2, and 1.3.

Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases

A method of inhibiting Ras function and therefore inhibiting cellular growth is disclosed. The method comprises the administration of a compound of Formula 1.0 STR1 Also disclosed are novel compounds of the formulas: STR2 Also disclosed are processes for making 3-substituted compounds of the Formulas 1.1, 1.2 and 1.3. Further disclosed are novel compounds which are intermediates in the processes for making the 3-substituted compounds of Formulas 1.1, 1.2, and 1.3.

Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases

A method of inhibiting Ras function and therefore inhibiting the abnormal growth of cells is disclosed. The method comprises the administration of a compound of Formula 1.0: STR1 to a biological system. In particular, the method inhibits the abnormal growth of cells in a mammal such as a human being. Novel compounds of formulas 5.0, 5.1 and 5.2, wherein R is --C(R20)(R21)(R46), and 5.3, 5.3A and 5.3B, wherein R is --N(R25)(R48), are disclosed. Also disclosed are processes for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3. Further disclosed are novel compounds which are intermediates in the process for making 3-substituted compounds of Formulas 5.0, 5.1, 5.2 and 5.3.

Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases

A method of inhibiting Ras function and therefore inhibiting cellular growth is disclosed. The method comprises the administration of a compound containing a tricyclic ring system to a biological system. In particular, the method inhibits cellular growth in a mammal such as a human being. Novel compounds of the formula: STR1 are disclosed. Also disclosed are processes for making 3-substituted compounds of Formula 4.0. Further disclosed are novel compounds which are intermediates in the processes for making the 3-substituted compounds of Formula 4.0.